Clinical trials: Hepatotoxicity
Liver Diseases, Liver Dysfunction
Monitoring the HePAtological TOXicity of Drugs (HePATOX)
Several drugs and chemotherapies seem to have an impact on the hepatological system. This study investigates reports of hepatological toxicities, including the International classification of disease ICD-10 for treatments in the…
- Conditions
- Liver Diseases, Liver Dysfunction, Liver Failure, Hepatotoxicity
- Trial name
- HePATOX (NCT03833297)
- Testing
- Drugs inducing hepatological toxicity
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Acetaminophen Overdose
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
- Trial name
- NCT01118663
- Testing
- Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cumberland Pharmaceuticals
Lymphoma, Hepatitis C Antibodies
Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy
In last few years, most researches about hepatic complication after chemotherapy focused on hepatitis B virus (HBV). With adequate prophylaxis and monitor, HBV-related hepatitis flares can be prevented.
- Conditions
- Lymphoma, Hepatitis C Antibodies, Drug Therapy
- Trial name
- NCT02588560
- Volunteers
- 38 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatitis, Tuberculosis
Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity
The purpose of the study is to estimate plasma drug levels ( free and total drug levels ) of rifampicin and other antituberculosis drugs and compare these drug levels in patients who develop drug induced hepatotoxicity versus…
- Trial name
- NCT01456845
- Where
- India
- Volunteers
- 110 people
- Sponsor
- All India Institute of Medical Sciences
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma.
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma
- Trial name
- NCT05602194
- Testing
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine
- Where
- 228 sites in United States, Canada
- Volunteers
- 440 people
- Sponsor
- Children's Oncology Group
Cancer
Hepatotoxicity Related to Protein Kinase Inhibitors
Although protein kinase inhibitors (PKIs) have proved effective in treating many cancers, few patients receiving PKIs may experience rare but life-threatening hepatotoxicity such as hepatic failure.
- Trial name
- NCT05430126
- Testing
- Protein Kinase Inhibitor
- Where
- China
- Volunteers
- 600,000 people
- Sponsor
- Central South University
Hepatitis, Tuberculosis
Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity
The purpose of this study is to evaluate plasma levels of hepatotoxic anti-tuberculous drugs (isoniazid, rifampicin, pyrazinamide plus significant metabolites) among patients on antituberculosis treatment (ATT) and compare the…
- Trial name
- NCT00929786
- Where
- 2 sites in India
- Volunteers
- 72 people
- Sponsor
- All India Institute of Medical Sciences
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030.
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Adenocarcinoma, Resectable Esophageal Cancer
- Trial name
- HEPATOXALI (NCT06649474)
- Testing
- assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acute Lymphoblastic Leukemia, Hepatotoxicity
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the most common cancer seen in pediatric oncology. The necessary chemotherapy for pediatric and adolescent and young adult (AYA) patients with ALL includes steroids, anthracyclines…
- Trial name
- NCT05501899
- Testing
- Levocarnitine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Orange County
Drug-Induced Liver Injury
Prevalence and Prognosis of Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is an important cause of acute liver damage that occurs when prescription medications, over-the-counter drugs, herbal products, or dietary supplements harm the liver.
- Trial name
- NCT07830901
- Volunteers
- 80 people
- Sponsor
- Assiut University
Immune-Mediated Hepatitis
Checkpoint Inhibitor-induced Liver Injury
In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and…
- Trial name
- ChILI (NCT04476563)
- Testing
- Obtaining biological samples
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- University of Nottingham
Rheumatoid Arthritis
Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches
The RA patients receiving leflunomide for more than one month, and not receiving other DMARDs (except hydroxychloroquine), will be enrolled to assess their disease activity.
- Trial name
- NCT04022525
- Testing
- Leflunomide 20Mg Tab
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Tuberculosis, Hepatotoxicity
NAT2 in Re-challenge of INH in Patients With Hepatitis
Apply the information of NAT2 genotyping into the re-challenge protocol of INH titration in patients with anti-TB medication induced hepatitis.
- Trial name
- NCT00728546
- Testing
- Isoniazid (Rifinah)
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Tuberculosis
The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs
Hepatitis is one of the most common adverse effect from anti-tuberculosis. Silymarin showed its efficacy to decreased serum alanine transaminase enzyme in animal models from recent study.
- Trial name
- NCT01800487
- Testing
- silymarin
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Ramathibodi Hospital
Drug-induced Disorder of Liver, Adverse Reaction to Drug
Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity
Drug metabolism in the liver is subject to large fluctuations (differences between women and men, people of different ethnic backgrounds, children and adults).
- Trial name
- NCT02353455
- Testing
- Blood sampling
- Where
- 5 sites in Australia, Germany and 3 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Andreas Benesic, MD
Acute Lymphoblastic Leukemia, Pancreatitis
PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL
The purpose of this study is to create a model enabling us to predict pancreatitis, hyperlipidemia and hepatotoxicity during treatment with PEG-Asparaginase in children with Acute Lymphoblastic Leukemia.
- Trial name
- AAP2008 (NCT01393249)
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Hepatotoxicity
Acetaminophen-induced Hepatotoxicity in Chronic Alcohol Abusers
It is widely believed that people who abuse alcohol can sustain a liver injury after taking doses of acetaminophen just above the recommended maximum dose.
- Trial name
- NCT00137059
- Testing
- acetaminophen sustained-release
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Dr. Marco L.A. Sivilotti
Chemical and Drug Induced Liver Injury
Hepatotoxicity of Antituberculosis Therapy (HAT) Study
Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe…
- Trial name
- HAT (NCT04159441)
- Testing
- None intervetion
- Volunteers
- 5,000 people
- Sponsor
- Huashan Hospital